Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the United States Patent and Trademark Office (USPTO) issued patent no. 11896719, entitled “New Pharmaceutical Compositions, on January 24, 2024 with validity as of today, February 13, 2024. This is Calliditas’ second patent for TARPEYO in the United States, and provides product protection until 2043
Calliditas Therapeutics AB（纳斯达克股票代码：CALT，纳斯达克斯德哥尔摩股票代码：CALTX）（“Calliditas”）今天宣布，美国专利商标局（USPTO）颁发了专利号11896719，标题为“新药物组合物”，于 2024 年 1 月 24 日生效，有效期截至今天，2024 年 2 月 13 日。这是 Calliditas 在美国获得的第二项 TARPEYO 专利，提供产品保护至 2043 年